Cargando…

KIT exon 10 variant (c.1621 A > C) single nucleotide polymorphism as predictor of GIST patient outcome

BACKGROUND: Tumor genotype plays a crucial role in clinical management of GIST. Whether genetic polymorphism of KIT may influence GIST patient outcome is unclear. METHODS: We investigated the biological and clinical significance of the presence of KIT exon 10 variant (c.1621 A > C), KIT(L541), in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brahmi, Mehdi, Alberti, Laurent, Dufresne, Armelle, Ray-Coquard, Isabelle, Cassier, Philippe, Meeus, Pierre, Decouvelaere, Anne-Valérie, Ranchère-Vince, Dominique, Blay, Jean-Yves
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619434/ https://www.ncbi.nlm.nih.gov/pubmed/26498480 http://dx.doi.org/10.1186/s12885-015-1817-5

Ejemplares similares

A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region
por: Cassier, P A, et al.
Publicado: (2010)

Pazopanib for the treatment of soft-tissue sarcoma
por: Heudel, Pierre, et al.
Publicado: (2012)

Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology
por: Dufresne, Armelle, et al.
Publicado: (2014)

Prognosis and predictive value of KIT exon 11 deletion in GISTs
por: Bachet, J-B, et al.
Publicado: (2009)

Prediction of desmoid tumor progression using miRNA expression profiling
por: Dufresne, Armelle, et al.
Publicado: (2015)

Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience
por: Levard, Alice, et al.
Publicado: (2013)

Novel Therapeutic Options for Solitary Fibrous Tumor: Antiangiogenic Therapy and Beyond
por: de Bernardi, Axel, et al.
Publicado: (2022)

Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients
por: Duffaud, Florence, et al.
Publicado: (2012)

Desmoplastic Small Round Cell Tumor: Current Management and Recent Findings
por: Dufresne, Armelle, et al.
Publicado: (2012)

The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors: The experiences of the pathologists of the French Sarcoma Group
por: Perrier, Lionel, et al.
Publicado: (2018)

Expanding the molecular spectrum of tenosynovial giant cell tumors
por: Gauduchon, Thibault, et al.
Publicado: (2022)

Survival impact of centralization and clinical guidelines for soft tissue sarcoma (A prospective and exhaustive population-based cohort)
por: Derbel, Olfa, et al.
Publicado: (2017)

Very long‐term survivors among patients with metastatic soft tissue sarcoma
por: Carbonnaux, Mélodie, et al.
Publicado: (2019)

Diagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients
por: Brahmi, Mehdi, et al.
Publicado: (2015)

Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment
por: Boilève, Alice, et al.
Publicado: (2020)

A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis
por: Kurtz, Jean-Emmanuel, et al.
Publicado: (2010)

miRNA Profiling: How to Bypass the Current Difficulties in the Diagnosis and Treatment of Sarcomas
por: Gougelet, Angélique, et al.
Publicado: (2011)

Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region
por: Lurkin, Antoine, et al.
Publicado: (2010)

Molecular Classification of Endometrial Stromal Sarcomas Using RNA Sequencing Defines Nosological and Prognostic Subgroups with Different Natural History
por: Brahmi, Mehdi, et al.
Publicado: (2020)

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
por: Blesius, Aurore, et al.
Publicado: (2011)

Efficacy and Safety of Adjuvant Radiotherapy in Re-excised Soft-tissue Sarcoma After Unplanned Resection
por: Allignet, Benoît, et al.
Publicado: (2023)

Refining Prognosis in Localized Gastrointestinal Stromal Tumor: Clinical Significance of Phosphatase and Tensin Homolog Low Expression and Gene Loss
por: Feng, Xiaolan, et al.
Publicado: (2022)

Evolution of Patterns of Care and Outcomes in the Real-Life Setting for Patients with Metastatic GIST Treated in Three French Expert Centers over Three Decades
por: Toulmonde, Maud, et al.
Publicado: (2023)

Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond
por: Fazel, Mina, et al.
Publicado: (2023)

Trabectedin and its potential in the treatment of soft tissue sarcoma
por: Cassier, Philippe A, et al.
Publicado: (2008)

Mutational Analysis of c-KIT and PDGFRA in Canine Gastrointestinal Stromal Tumors (GISTs)
por: Morini, Maria, et al.
Publicado: (2022)

Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT)
por: Brahmi, Mehdi, et al.
Publicado: (2020)

Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing
por: Ducimetière, Françoise, et al.
Publicado: (2011)

Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
por: Vincenzi, Bruno, et al.
Publicado: (2022)

Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients
por: Mohammadi, Mahmoud, et al.
Publicado: (2022)

Therapeutic relevance of molecular screening program in patients with metastatic sarcoma: Analysis from the ProfiLER 01 trial
por: Arnaud-Coffin, Patrick, et al.
Publicado: (2020)

LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma
por: Klug, Lillian R., et al.
Publicado: (2018)

Gene Expression Patterns of Hemizygous and Heterozygous KIT Mutations Suggest Distinct Oncogenic Pathways: A Study in NIH3T3 Cell Lines and GIST Samples
por: Bachet, Jean-Baptiste, et al.
Publicado: (2013)

The Frequency of Mutations in Exon 11 of the c-kit Gene in Patients With Leukemia
por: Hussain, Syed Rizwan, et al.
Publicado: (2012)

Secondary KIT mutations: the GIST of drug resistance and sensitivity
por: Napolitano, Andrea, et al.
Publicado: (2019)

Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H
por: Revheim, Mona-Elisabeth, et al.
Publicado: (2013)

Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis
por: Vincenzi, Bruno, et al.
Publicado: (2015)

TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials
por: Nassif, Elise F., et al.
Publicado: (2021)

Tocilizumab for the treatment of paraneoplastic inflammatory syndrome associated with angiomatoid fibrous histiocytoma
por: Eberst, Lauriane, et al.
Publicado: (2020)

Mutations in C-KIT exon 11 in canine cutaneous mast cell tumors
por: Neto, Rafael T, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_24unn580pdfg8jqjvqj02si0mp